FdaApplication
NDA 214958
Identifiers
- fda_app_no: NDA214958
Properties
| Property | Value |
|---|---|
| applicant_name | BRISTOL MYERS SQUIBB CO |
| application_type | NDA |
| approval_date | 2022-09-09 |
Revenue by product
SOTYKTU
| Period | Revenue |
|---|---|
| Q2 2026 | $87.0M |
| Q1 2026 | $69.0M |
| Q4 2025 | $85.0M |
| Q3 2025 | $80.0M |
| Q2 2025 | $70.0M |
| Q1 2025 | $55.0M |
| Q4 2024 | $83.0M |
| Q3 2024 | $66.0M |
| Q2 2024 | $53.0M |
| Q1 2024 | $44.0M |
| Q4 2023 | $63.0M |
| Q3 2023 | $66.0M |
| Q2 2023 | $25.0M |
| Q1 2023 | $16.0M |
| Q4 2022 | $7.0M |
| Q3 2022 | $1.0M |
| Q2 2022 | $0.0M |
| Q1 2022 | $0.0M |
| Q4 2021 | $0.0M |
| Q3 2021 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| SOTYKTU | DEUCRAVACITINIB | 6MG | TABLET;ORAL |
1 product